PCN18 ECONOMIC EVALUATION OF SUNITINIB VS. IMATINIB IN SECOND LINE FOR GASTROINTESTINAL TUMOR (GIST) IN BRAZIL

MLA

C Hashizume, et al. “Pcn18 Economic Evaluation of Sunitinib Vs. Imatinib in Second Line for Gastrointestinal Tumor (Gist) in Brazil.” Value in Health, no. 7, p. A496. EBSCOhost, https://doi.org/10.1016/S1098-3015(10)75345-6. Accessed 5 Feb. 2025.

APA

C Hashizume, N Teich, & W Follador. (n.d.). Pcn18 Economic Evaluation of Sunitinib Vs. Imatinib in Second Line for Gastrointestinal Tumor (Gist) in Brazil. Value in Health, 7, A496. https://doi.org/10.1016/S1098-3015(10)75345-6

Chicago

C Hashizume, N Teich, and W Follador. 2025. “Pcn18 Economic Evaluation of Sunitinib Vs. Imatinib in Second Line for Gastrointestinal Tumor (Gist) in Brazil.” Value in Health, no. 7: A496. Accessed February 5. doi:10.1016/S1098-3015(10)75345-6.